Pain and fatigue may occur together during sustained exhausting muscle contractions, particularly as the limit of endurance is approached, and both can restrict muscle performance. Patients with neuromuscular disorders may have chronic myofascial pain (e.g. fibromyalgia) or contraction-induced pain (e.g. in metabolic myopathies). In some patients these two types of pain may coexist and both may inhibit central motor drive during exercise. Little is known about the central motor adaptations that occur in patients with neuromuscular disorders and how the effects of pain are mediated. Transcranial magnetic brain stimulation has made it possible to investigate the changes in excitability of the central motor pathway during fatiguing muscle activity and have thrown light on the mechanisms of fatigue in normal subjects and individuals with chronic fatigue syndrome and multiple sclerosis, but there have been few studies in patients with neuromuscular disorders. Repetitive magnetic brain stimulation protocols can now be used to modulate the excitability of the motor system during exercise to delay the onset of peripheral fatigue, and to reduce chronic pain. The possible application of these techniques in patients with neuromuscular disorders warrants further investigation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nmd.2012.10.003 | DOI Listing |
Asian Pac Isl Nurs J
January 2025
Nursing Care Research Center, Clinical Sciences Institute, Nursing Faculty, Baqiyatallah University of Medical Sciences, Vanak Square, Tehran, Iran, 98 9127297199.
Background: Neuromuscular disorders (NMDs) constitute a heterogeneous group of disorders that affect motor neurons, neuromuscular junctions, and muscle fibers, resulting in symptoms such as muscle weakness, fatigue, and reduced mobility. These conditions significantly affect patients' quality of life and impose a substantial burden on caregivers. Spinal muscular atrophy (SMA) is a relatively common NMD in children that presents in various types with varying degrees of severity.
View Article and Find Full Text PDFAmyotroph Lateral Scler Frontotemporal Degener
January 2025
2nd Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.
Motor Neuron Diseases (MNDs), familial and sporadic, are progressive neurodegenerative disorders that, for an extended period in the past, were considered purely motor disorders. During the course of the disease, however, some patients exhibit concomitant non-motor signs; thus, MNDs are currently perceived as multisystem disorders. Assessment of non-motor symptoms is usually performed clinically, although laboratory tests can also be routinely used to objectively evaluate these symptoms.
View Article and Find Full Text PDFJ Anesth Analg Crit Care
January 2025
Department of Anesthesia and Intensive Care, Agostino Gemelli IRCCS University Polyclinic Foundation, Rome, Italy.
Background: Neuromuscular blocking agents (NMBAs) are routinely used in anesthesia practice. An undetected, incomplete recovery of neuromuscular function at the end of surgery potentially exposes patients to clinical deterioration in the postoperative period. The aim of this study was to investigate the incidence of postoperative residual neuromuscular blockade (RNMB) in a cohort of patients receiving NMBAs.
View Article and Find Full Text PDFArch Pediatr
January 2025
CMR Neuromusculaire, Service de génétique médicale, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address:
Background: Myotonia is the main feature of both myotonic dystrophy (DM) and non-dystrophic myotonia (NDM). It is felt as stiffness, pain, fatigue, and weakness. In France, mexiletine, a non-selective voltage-gated sodium channel blocker, is approved for the treatment of myotonia in adults with NDM, and it has a temporary recommendation for use in the symptomatic treatment of DM in adults.
View Article and Find Full Text PDFJ Neurol Sci
January 2025
Neuromuscular Diseases Unit, Department of Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain; Department de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.
Background: The development of new biomarkers is essential to improve diagnostic accuracy and guide treatment decisions in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The aim of this study was to investigate the utility of the serum neurofilament light chain (sNfL) level as a marker for disability and response to immunomodulatory treatment in patients with CIDP.
Methods: This prospective, single-center, observational study included 38 patients with CIDP: 19 treatment-naive (CIDP-I) patients assessed before and after the initiation of immunomodulatory therapy and 19 stable patients on maintenance immunoglobulins (CIDP-M).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!